The mammalian target of rapamycin (mTOR) kinase is a master regulator of protein synthesis that couples nutrient sensing to cell growth and cancer. However, the downstream translationally regulated nodes of gene expression that may direct cancer development are poorly characterized. Using ribosome profiling, we uncover specialized translation of the prostate cancer genome by oncogenic mTOR signalling, revealing a remarkably specific repertoire of genes involved in cell proliferation, metabolism and invasion. We extend these findings by functionally characterizing a class of translationally controlled pro-invasion messenger RNAs that we show direct prostate cancer invasion and metastasis downstream of oncogenic mTOR signalling. Furthermore, we develop a clinically relevant ATP site inhibitor of mTOR, INK128, which reprograms this gene expression signature with therapeutic benefit for prostate cancer metastasis, for which there is presently no cure. Together, these findings extend our understanding of how the 'cancerous' translation machinery steers specific cancer cell behaviours, including metastasis, and may be therapeutically targeted.
It is unknown whether specialized networks of translationally controlled mRNAs can direct cancer initiation and progression, thereby mirroring cooperativity that has mainly been observed at the level of transcriptional control. This is an important question, as key oncogenic signalling molecules, such as the mTOR kinase, directly regulate the activity of general translation factors 1, 2 . Downstream of the phosphatidylinositol-3-OH kinase (PI(3)K)-AKT signalling pathway, mTOR assembles with either raptor or rictor to form two distinct complexes: mTORC1 and mTORC2 (refs 3, 4) . The major regulators of protein synthesis downstream of mTORC1 are 4EBP1 (also called EIF4EBP1) and p70S6K1/2 (refs 1, 2). 4EBP1 negatively regulates eIF4E, a key rate-limiting initiation factor for cap-dependent translation. Phosphorylation of 4EBP1 by mTORC1 leads to its dissociation from eIF4E, allowing translation initiation complex formation at the 59 end of mRNAs 5 . The mTOR-dependent phosphorylation of p70S6K1/2 also promotes translation initiation as well as elongation 6 . At a genome-wide level, it remains poorly understood whether and how activation of these regulators of protein synthesis may produce specific changes in gene expression networks that direct cancer development. Here we use a powerful new technology known as ribosome profiling to delineate the translational landscape of the cancer genome at a codon-by-codon resolution upon pharmacological inhibition of mTOR 7 . Our findings provide genome-wide characterization of translationally controlled mRNAs downstream of oncogenic mTOR signalling and delineate their functional roles in cancer development. Moreover, we determine the efficacy of a novel clinically relevant mTOR inhibitor that we developed, INK128, which specifically targets this cancer program.
Ribosome profiling of the prostate cancer genome mTOR is deregulated in nearly 100% of advanced human prostate cancers 8 , and genetic findings in mouse models implicate mTOR hyperactivation in prostate cancer initiation [9] [10] [11] . Given the critical role for mTOR in prostate cancer, we used PC3 human prostate cancer cells, where mTOR is constitutively hyperactivated, to delineate translationally controlled gene expression networks upon complete or partial mTOR inhibition. We optimized ribosome profiling to assess quantitatively ribosome occupancy genome-wide in cancer cells 7 . In brief, ribosome-protected mRNA fragments were deep-sequenced to determine the number of ribosomes engaged in translating specific mRNAs ( Supplementary Fig. 1a and Methods). Treatment of PC3 cells with PP242 (refs 12, 13) , an mTOR ATP site inhibitor, significantly inhibits the activity of the three primary downstream mTOR effectors 4EBP1, p70S6K1/2 and AKT. On the contrary, rapamycin, an allosteric mTOR inhibitor, only blocks p70S6K1/2 activity in these cells ( Supplementary Fig. 1b ). We used short 3-h drug treatments, which precede alterations in de novo protein synthesis, to capture direct changes in mTOR-dependent gene expression by ribosome profiling and to minimize compensatory feedback mechanisms (Supplementary Fig. 1c-f) .
Ribosome profiling revealed 144 target mRNAs selectively decreased at the translational level upon PP242 treatment (log 2 #21.5 (false discovery rate ,0.05)) compared to rapamycin treatment, with limited changes in transcription ( Fig. 1a and Supplementary Figs 2a, b and 3-10). The fact that at this time point rapamycin treatment did not markedly affect gene expression is consistent with incomplete allosteric inhibition of mTOR activity ( Supplementary Fig. 1b) . By monitoring footprints of translating 80S ribosomes, our findings show that the effects of PP242 are largely at the level of translation initiation and not elongation ( Supplementary Fig. 3 ). It has been proposed that mRNAs translationally regulated by mTOR may contain long 59 untranslated regions (59 UTRs) with complex RNA secondary structures. On the contrary, ribosome profiling revealed that mTORresponsive 59 UTRs possess less complex features (Fig. 1b-d) , providing a unique data set to investigate the nature of regulatory elements that render these mRNAs mTOR-sensitive. It has been previously shown that some mTOR translationally regulated mRNAs, most notably those involved in protein synthesis, possess a 59 terminal oligopyrimidine tract (59 TOP) 14, 15 that is regulated by distinct transacting factors 16, 17 . Of the 144 mTOR-sensitive target genes, 68% possess a 59 TOP. However, as the 59 TOP is not present in all mTOR-sensitive mRNAs, we next asked whether other 59 UTR consensus sequences may exist. Strikingly, 63% of mTOR target mRNAs possess what we have termed a pyrimidine-rich translational element (PRTE) within their 59 UTRs (P 5 3.2 3 10
211
). This element, unlike the 59 TOP sequence, consists of an invariant uridine at position 6 flanked by pyrimidines and, importantly, does not reside at position 11 of the 59 UTR ( Supplementary Figs 2c and 7) . We found that 89% of the mTOR-responsive genes possess a PRTE and/or 59 TOP, making the presence of one or both sequences a strong predictor for mTOR sensitivity (Supplementary Figs 2d and 7) . Notably, mRNA isoforms arising from distinct transcription start sites may possess both a 59 TOP and a PRTE. Moreover, given the significant number of mRNAs that contain both the PRTE and 59 TOP, a functional interplay may exist between these regulatory elements. Future studies are required to determine the regulatory logic for how these sequences either independently or coordinately confer mTOR responsiveness. Multiple cis-acting elements within specific 59 UTRs could reflect regulation by distinct mTOR effectors. For example, our findings show that the PRTE imparts translational control specificity to 4EBP1 activity (see below) . Surprisingly, mTOR-sensitive genes stratify into unique functional categories that may promote cancer development and progression, including cellular invasion (P 5 0.009), cell proliferation (P 5 0.04), metabolism (P 5 0.0002) and regulators of protein modification (P 5 0.01) (Fig. 1e) . The largest fraction of mTOR-responsive mRNAs cluster into a node consisting of key components of the translational apparatus: 70 ribosomal proteins, 6 elongation factors, and 4 translation initiation factors (P 5 7.5 3 10 282 ) ( Fig. 1e and Supplementary Fig. 5 ). Therefore, this class of mTOR-responsive mRNAs may represent an important regulon that sustains the elevated protein synthetic capacity of cancer cells.
Notably, the second largest node of mTOR translationally regulated genes comprises bona fide cell invasion and metastasis mRNAs and putative regulators of this process (Fig. 1e) . This group includes YB1 (Y-box binding protein 1; also called YBX1), vimentin, MTA1 (metastasis associated 1) and CD44 ( Supplementary Fig. 11a ). YB1 
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regulates the post-transcriptional expression of a network of invasion genes 18 . Vimentin, an intermediate filament protein, is highly upregulated during the epithelial-to-mesenchymal transition associated with cellular invasion 19 . MTA1, a putative chromatin-remodelling protein, is overexpressed in invasive human prostate cancer 20 and has been shown to drive cancer metastasis by promoting neoangiogenesis 21 . CD44 is commonly overexpressed in tumour-initiating cells and is implicated in prostate cancer metastasis 22 . Consistent with their status as mTOR sensitive genes, YB1, vimentin, MTA1 and CD44 all possess a PRTE ( Supplementary Fig. 5 ). Vimentin and CD44 also possess a 59 TOP ( Supplementary Fig. 7 ). To test the functional role of the PRTE in mediating translational control, we mutated the PRTE within the 59 UTR of YB1, which rendered the YB1 59 UTR insensitive to inhibition by 4EBP1 (Supplementary Fig. 11b ). These findings highlight a novel cis-regulatory element that may modulate translational control of subsets of mRNAs upon mTOR activation. Moreover, ribosome profiling reveals unexpected transcript-specific translational control, mediated by oncogenic mTOR signalling, including a distinct set of pro-invasion and metastasis genes.
Translation of pro-invasion mRNAs by mTOR
We next extended the use of the mTOR pharmacological tools used in ribosome profiling towards functional characterization of the newly identified mTOR-sensitive cell invasion gene signature. To this end, we developed a new clinical-grade mTOR ATP site inhibitor, INK128, derived from the PP242 chemical scaffold (Fig. 1f) . In brief, a structureguided optimization of pyrazolopyrimidine derivatives was performed (see INK128 chemical synthesis in Supplementary Information) that improved oral bioavailability while retaining mTOR kinase potency and selectivity. INK128 was selected for clinical studies on the basis of its high potency (1.4 nM inhibition constant (K i )), selectivity for mTOR, low molecular mass, and favourable pharmaceutical properties (Supplementary Figs 12 and 13).
Using either PP242 or INK128, we observed a selective decrease in the expression of YB1, MTA1, vimentin and CD44 at the protein but not transcript level in PC3 cells starting at 6 h of treatment, which precedes any decrease in de novo protein synthesis ( Fig. 1g and Supplementary Figs 1c, d, 14 and 15). In contrast, rapamycin treatment did not alter their expression ( Fig. 1g and Supplementary Fig. 14a ). Similar findings were observed using a broad panel of metastatic cell lines of distinct histological origins ( Supplementary Fig. 16 ). The fourgene invasion signature is positively regulated by mTOR hyperactivation, as silencing PTEN expression increased their protein but not mRNA expression levels ( Supplementary Fig. 17 ). We next investigated the effects of mTOR ATP site inhibitors on prostate cancer cell migration and invasion. We found that INK128, but not rapamycin, decreases the invasive potential of PC3 prostate cancer cells (Fig. 2a) . Furthermore, INK128 inhibits cancer cell migration starting at 6 h of treatment, precisely correlating with when decreases in the expression of pro-invasion genes are evident, but preceding any changes in the cell cycle or overall global protein synthesis (Fig. 2b , c, and Supplementary Figs 1c, e, f, 14b and 18).
Among the genes comprising the pro-invasion signature, YB1 has been shown to act directly as a translation factor that controls expression of a larger set of genes involved in breast cancer cell invasion 18 . Notably, YB1 translationally regulated target mRNAs, including SNAIL1 (also called SNAI), LEF1 and TWIST1, decreased at the protein but not transcript level upon YB1 knockdown in PC3 cells (Supplementary Figs 19 and 20) . To determine the functional role of YB1 in prostate cancer cell invasion, we silenced YB1 gene expression in PC3 cells, and observed a 50% reduction in cell invasion (Fig. 2d) . Similarly, knockdown of MTA1, CD44, or vimentin also inhibited prostate cancer cell invasion ( Fig. 2d and Supplementary Fig. 19 ). These mTOR target mRNAs may be sufficient to endow primary prostate cells with invasive features, as overexpression of YB1 and/or MTA1 ( Supplementary Fig. 21a ) in BPH-1 cells, an untransformed Supplementary  Fig. 23a ). e, Representative western blot from three independent experiments of wild type (WT) and 4EBP1/4EBP2 double knockout (DKO) MEFs treated with INK128 for 24 h. f, Representative western blot from two independent experiments of wild-type and mSin1 2/2 (also called Mapkap1 
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prostate epithelial cell line, increased the invasive capacity of these cells in an additive manner (Fig. 2e) . Notably, the effects of YB1 and MTA1 on cell invasion are independent from any effect on cell proliferation in both knockdown or overexpression studies (Supplementary Fig. 21b, c) . Therefore, translational control of pro-invasion mRNAs by oncogenic mTOR signalling alters the ability of epithelial cells to migrate and invade, a key feature of cancer metastasis.
Dissecting mTOR translational effectors
We sought to determine the molecular mechanism by which proinvasion genes are regulated at the translational level and why these mRNAs are sensitive to INK128 but not rapamycin. To this end, we investigated whether the translational regulators downstream mTORC1, 4EBP1 and/or p70S6K1/2, control the expression of these mTOR-sensitive targets. We generated a human prostate cancer cell line that stably expresses a doxycycline-inducible dominant-negative mutant of 4EBP1 (4EBP1 M ) (Fig. 3a ) 13 . This mutant binds to eIF4E, decreasing its hyperactivation without inhibiting general mTORC1 function ( Supplementary Fig. 22a) . Notably, expression of 4EBP1 M does not alter global protein synthesis ( Supplementary Fig. 22b ), probably because endogenous 4EBP1 and 4EBP2 proteins retain their ability to bind to eIF4E ( Supplementary Fig. 22c ) 13 . Upon induction of 4EBP1 M , YB1, vimentin, CD44 and MTA1 decrease at the protein but not mRNA level, whereas pharmacological inhibition of p70S6K1/2 with DG-2 (ref. 23 ) had no effect (Fig. 3b, c and Supplementary Fig. 22d ). Next, we tested whether INK128 decreases expression of the four invasion genes through the 4EBP-eIF4E axis. Notably, knockdown of 4EBP1 and 4EBP2 in PC3 cells or using 4EBP1 and 4EBP2 double knockout mouse embryonic fibroblasts (MEFs) 24 reduced the ability of INK128 to decrease expression of these pro-invasion mRNAs (Fig. 3d, e and Supplementary Fig. 23 ). Furthermore, ablation of mTORC2 activity 25 had no effect on the expression of these mRNAs or responsiveness to INK128 (Fig. 3f and Supplementary Fig. 24a-c) . Next, we determined the effect of 4EBP1 M on human prostate cancer cell invasion. The expression of 4EBP1 M resulted in a significant decrease in prostate cancer cell invasion without affecting the cell cycle, whereas DG-2 had no effect ( Fig. 3g and Supplementary Fig. 24d ). These findings demonstrate that eIF4E hyperactivation downstream of oncogenic mTOR regulates translational control of the pro-invasion mRNAs and provides an explanation for the selective targeting of this gene signature by mTOR ATP site inhibitors.
Examining cell invasion networks in vivo
Both CK5
1 and CK8 1 prostate epithelial cells have been implicated in the initiation of prostate cancer upon loss of PTEN 26, 27 . Pten
) mice are an ideal model of prostate cancer because they display distinct stages of cancer development (prostatic intraepithelial neoplasia, invasive adenocarcinoma, and metastasis) 28 . However, the expression patterns of YB1, vimentin, CD44 and MTA1 in prostate basal (CK5
1
) and luminal (CK8 1 ) epithelial cells have not been characterized. We therefore analysed their expression patterns in the Pten L/L prostate cancer mouse model, where mTOR is constitutively hyperactivated 9, 28 . We found that YB1 localizes to the cytoplasm and nucleus of CK5 1 and CK8 1 prostate epithelial cells, consistent with its ability to shuttle between the two cellular compartments (Fig. 4a, b and Supplementary Fig. 25a, b ) 18, 29 . MTA1 expression is exclusively nuclear in both cell types (Fig. 4c, d ). Of note, CD44, together with other cellsurface markers, has been used to isolate a rare prostate stem-cell population 30 . We observed expression of CD44 within a subset of CK5 1 and CK8 1 epithelial cells (Fig. 4e, f) . In contrast, vimentin is not detected in either cell type (Fig. 4g) . We next determined the impact of mTOR hyperactivation on the expression pattern of the pro-invasion gene signature. YB1, MTA1 and CD44 protein, but not transcript, levels were significantly increased in both Pten L/L luminal and basal epithelial cells compared to wild type ( Fig. 4h and Supplementary Fig. 25c-e) . Interestingly, a subset of Pten L/L luminal epithelial cells ectopically expresses vimentin at aberrantly high levels, with a perinuclear distribution ( Fig. 4g and Supplementary Fig. 25f, g ) suggesting that these cells may have acquired some mesenchymal-like features. Consistent with these findings, perinuclear vimentin localization is associated with invasive features of human prostate cancer cells 31 and changes Supplementary Fig. 25b ); *P , 0.0001, **P 5 0.0004, t-test).
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in cell polarity in actively moving fibroblasts 32 . These studies reveal a unique, translationally controlled signature of gene expression downstream of mTOR hyperactivation in a cancer-initiating subset of prostate epithelial cells.
Targeting prostate cancer metastasis
The most significant pre-clinical extension of this work would be to determine the therapeutic benefit of INK128 in reprogramming expression of the mTOR-dependent pro-invasion gene signature and prostate cancer metastasis directly in vivo. This is underscored by the clinical inefficacy of allosteric mTOR inhibition towards the lethal form of metastatic human prostate cancer 33, 34 . Importantly, in our preclinical trial of RAD001 (rapalog) versus INK128 in Pten L/L mice, 4EBP1 and p70S6K1/2 phosphorylation was completely restored to wild-type levels after treatment with INK128, whereas RAD001 only decreased p70S6K1/2 phosphorylation levels ( Supplementary Fig. 26a, b) . We next determined the cellular consequences of complete versus partial mTOR inhibition during distinct stages of prostate cancer. INK128 treatment resulted in a 50% decrease in prostatic intraepithelial neoplasia (PIN) lesions in Pten L/L mice that was associated with decreased proliferation and a tenfold increase in apoptosis ( Supplementary Fig. 26d-f) . Notably, 
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the unique cytotoxic properties of INK128 treatment in Pten L/L mice were evidenced by a marked reduction in prostate cancer volume. In addition, and consistent with these findings, INK128 induced programmed cell death in multiple cancer cell lines ( Supplementary Fig.  27a, b) . In contrast, RAD001 treatment mainly had cytostatic effects leading to only partial regression of PIN lesions associated with a limited decrease in cell proliferation and no significant effect on apoptosis ( Supplementary Fig. 26c-f) .
We extended the preclinical trial by examining the effects of INK128 treatment on the pro-invasion gene signature and prostate cancer metastasis, which is incurable and the primary cause of patient mortality. Cell invasion is the critical first step in metastasis, required for systemic dissemination. In Pten L/L mice after the onset of PIN, a subset of prostate glands show characteristics of luminal epithelial cell invasion by 12 months (Fig. 5a and Supplementary Fig. 27c ) 28 . After 12 months of age, Pten L/L mice develop lymph-node metastases and these cells maintain strong YB1 and MTA1 expression (Fig. 5b) . We further extended these findings directly to human prostate cancer patient specimens, observing that YB1 expression levels increase in a stepwise fashion from normal prostate to castration-resistant prostate cancer (CRPC), an advanced form of the disease associated with increased metastatic potential (Fig. 5c) . MTA1 levels exhibit similar increases 20 . In human prostate cancer, high-grade primary tumours that display invasive features are more likely to develop systemic metastasis than low-grade non-invasive tumours 35, 36 . Remarkably, treatment with INK128 completely blocked the progression of invasive prostate cancer locally in the prostate gland, and profoundly inhibited the total number and size of distant metastases (Fig. 5d-f) . This was associated with a marked decrease in the expression of YB1, vimentin, CD44 and MTA1 at the protein, but not transcript, level in specific epithelial cell types within pre-invasive PIN lesions in Pten L/L mice ( Fig. 5g and Supplementary Fig. 25c ). Together, these findings reveal an unexpected role for oncogenic mTOR signalling in control of a pro-invasion translational program that, along with the lethal metastatic form of prostate cancer, can be efficiently targeted with clinically relevant mTOR ATP site inhibitors.
Discussion
Here we used ribosome profiling to generate a comprehensive map of translationally controlled mTOR targets in cancer that surprisingly stratify into specific cellular processes including proliferation, metabolism, protein synthesis and invasion (Fig. 1e) . The effects of this translational control program are probably broad, converging on many subclasses of mRNAs that may cooperate towards distinct steps in cancer development and therapeutic response. This is supported by our in vivo findings where we developed a novel clinically relevant mTOR inhibitor, INK128, that significantly abrogates multiple aspects of prostate cancer development by inducing apoptosis as well as inhibiting cell proliferation, invasion and metastasis (Fig. 5d-g and Supplementary Fig. 26c-f) . The superiority of INK128 as an mTOR inhibitor is also evident in its ability to reprogram the mTOR oncogenic translational program in prostate cancer, which is not achieved by rapalog treatment. Of note, however, the sensitivity of cells from distinct histological origins to ATP site versus allosteric inhibitors of mTOR may differ. For example, the Jurkat lymphoid cell line is particularly sensitive to rapamycin treatment 37 . One of the most novel nodes of mTOR translationally controlled genes are those that cooperatively control, at least in part, the cellular invasive features of human prostate cancer cells (Figs 1g, 2 and 3b, g ). Translational control of these mRNAs relies on the 4EBP1-eIF4E axis and is thereby specifically druggable with potent mTOR ATP site inhibitors, which, unlike rapamycin, target mTOR-dependent 4EBP1 phosphorylation (Figs 1g, 3d , e and 5g, and Supplementary  Figs 1b, 23 and 26b ). This has significant therapeutic implications not only for advanced prostate cancer but also for multiple metastatic cancers where we show that translational control of pro-invasion mRNAs is sensitive to ATP site inhibitors of mTOR (Supplementary Fig. 16) . Thereby, these studies link translational regulation to the poorly understood mechanisms underlying cancer metastasis. Intriguingly, various components of the translation machinery, including oncogenic eIF4E 38 , localize to the leading edge of migrating fibroblasts 39 . This may allow spatially controlled translation of mRNAs important for cell migration, providing a rapid and specific response in transducing a migration program that could be co-opted at the invasive edge of metastatic cancer cells. Together, these studies reveal that the ability of mTOR to phosphorylate general translation factors results in exquisite transcript-specific translational control of key mRNAs that may cooperate in distinct steps of cancer initiation and progression, with significant implications for therapeutic intervention.
METHODS SUMMARY
Mice. Pten loxp/loxp and Pb-cre mice were obtained from Jackson Laboratories and Mouse Models of Human Cancers Consortium (MMHCC) and maintained in the C57BL/6 background. Ribosome profiling. PC3 lysates were subjected to ribosome footprinting by nuclease treatment. Ribosome-protected and alkaline digested poly(A) mRNA fragments were purified and deep sequencing libraries were generated. Ribosome footprint and RNA-seq sequencing reads were aligned against a library of transcripts from the UCSC Known Genes database GRCh37/hg19. Read density profiles were constructed for the canonical transcript of each gene. The average read density per codon was computed for the coding sequence of each transcript. Average read density was used to determine mRNA abundance (RNA-seq reads), ribosome occupancy of mRNAs (foot print reads), and translational efficiency (foot print reads/RNA-seq reads). Immunofluorescence. Paraffin-embedded mouse prostates and lymph nodes were deparaffinized and rehydrated using CitriSolv (Fisher) and serial ethanol washes. Antigen unmasking was performed using Citrate pH 6 (Vector Labs). Sections were blocked in 5% goat serum, 1% BSA in TBS. Various primary antibodies were used at dilutions between 1:50 and 1:500 (see Methods), followed by incubation with appropriate conjugated secondary antibodies. Samples were mounted with DAPI Hardset Mounting Medium (Vector Lab). A Zeiss Spinning Disc confocal (Zeiss, CSU-X1) was used to image the tissues. Individual cells were quantified for mean fluorescence intensity using the Axiovision (Zeiss, Release 4.8) densitometric tool.
METHODS
Mice. Pten loxp/loxp and Pb-cre mice where obtained from Jackson Laboratories and Mouse Models of Human Cancers Consortium (MMHCC), respectively, and maintained in the C57BL/6 background. Mice were maintained under specific pathogen-free conditions, and experiments were performed in compliance with institutional guidelines as approved by the Institutional Animal Care and Use Committee of UCSF. Cell culture and reagents. Human cell lines were obtained from the ATCC and maintained in the appropriate medium with supplements as suggested by ATCC. Wild-type, mSin1
2/2 (provided by B. Su), and 4EBP1/4EBP2 double knockout MEFs (provided by N. Sonenberg) were cultured as previously described 24, 25 . SMARTvector 2.0 (Thermo Scientific) lentiviral shRNA constructs were used to knock down PTEN (SH-003023-02-10). For generation of GFP-labelled PC3 cells, SMARTvector 2.0 lentiviral empty vector control particles that contain TurboGFP (S-004000-01) were used.
) and 4EBP2 (L-018671) pooled siRNAs were purchased from Thermo Scientific. Intellikine provided INK128 and PP242, which were used at 200 nM and 2.5 mM in cell-based assays unless otherwise specified. RAD001 was obtained from LC Laboratories. DG-2 was provided by K. Shokat and used at 20 mM in cell-based assays. Rapamycin was purchased from Calbiochem and used at 50 nM in cell-based assays. Doxycyline (Sigma) was used at 1 mg ml 21 in 4EBP1 M induction assays. Lipofectamine 2000 (Invitrogen) was used to transfect cancer cell lines with siRNA. Amaxa Cell Line Nucleofector Kit R (Lonza) was used to electroporate BPH-1 cells with over expression vectors. The 4EBP1 M has been previously described 13 . Plasmids. pcDNA3-HA-YB1 was provided by V. Evdokimova. pCMV6-Myk-DDK-MTA1 was purchased from Origene. pGL3-Promoter was purchased from Promega. To clone the 59 UTR of YB1 into pGL3-Promoter, the entire 59 UTR sequence of YB1 was amplified from PC3 cDNA. PCR fragments were digested with HindIII and NcoI and ligated into the corresponding sites of pGL3-Promoter. The PRTE sequence at position 120-34 in the YB1 59 UTR (UCSC kgID uc001chs.2) was mutated using the QuikChange Site-Directed Mutagenesis Kit following the manufacturer's protocol (Stratagene). Ribosome profiling. PC3 cells were treated with rapamycin (50 nM; Calbiochem) or PP242 (2.5 mM; Intellikine) for 3 h. Cells were subsequently treated with cycloheximide (100 mg ml 21 ; Sigma) and detergent lysis was performed in the dish. The lysate was treated with DNase and clarified, and a sample was taken for RNA-seq analysis. Lysates were subjected to ribosome foot printing by nuclease treatment. Ribosome-protected fragments were purified, and deep sequencing libraries were generated from these fragments, as well as from poly(A) mRNA purified from non-nuclease-treated lysates. These libraries were analysed by sequencing on an Illumina GAII.
Each sequencing run resulted in approximately 20-25 million raw reads per sample, of which 5-12 million unique reads were used for subsequent analysis. Ribosome footprint and RNA-seq sequencing reads were aligned against a library of transcripts from the UCSC Known Genes database GRCh37/hg19. The first 25 nucleotides of each read were aligned using Bowtie and this initial alignment was then extended to encompass the full fragment-derived portion of the sequencing read while excluding the linker sequence. Read density profiles were then constructed for the canonical transcript of each gene, using only reads with 0 or 1 total mismatches between the read sequence and the reference sequence, comprised of the transcript fragment followed by the linker sequence. Footprint reads were assigned to an A site nucleotide at position 115 to 117 of the alignment, based on the total fragment length; mRNA reads were assigned to the first nucleotide of the alignment. The average read density per codon was then computed for the coding sequence of each transcript, excluding the first 15 and last 5 codons, which can display atypical ribosome accumulation.
Average read density was used as a measure of mRNA abundance (RNA-seq reads) and of protein synthesis (ribosome profiling reads). For most analyses, genes were filtered to require at least 256 reads in the relevant RNA-seq samples. Translational efficiency was computed as the ratio of ribosome footprint read density to RNA-seq read density, scaled to normalize the translational efficiency of the median gene to 1.0 after excluding regulated genes (log 2 fold-change 61.5 after normalizing for the all-gene median). Changes in protein synthesis, mRNA abundance and translational efficiency were similarly computed as the ratio of read densities between different samples, normalized to give the median gene a ratio of 1.0. This normalization corrects for differences in the absolute number of sequencing reads obtained for different libraries. 3,977 (replicate 1), and 5,333 (replicate 2) unique mRNAs passed a preset read threshold of 256 reads for singlegene quantification for all treatment conditions. Western blot analysis. Western blot analysis was performed as previously described 13 with antibodies specific to phospho-AKT S473 (Cell Signaling), AKT Laboratory) . qPCR analysis. RNA was isolated using the manufacturer's protocol for RNA extraction with TRIzol Reagent (Invitrogen) using the Pure Link RNA mini kit (Invitrogen). RNA was Dnase-treated with Pure Link Dnase (Invitrogen). Dnasetreated RNA was transcribed to cDNA with SuperScript III First-Strand Synthesis System for RT-PCR (Invitrogen), and 1 ml of cDNA was used to run a SYBR green detection qPCR assay (SYBR Green Supermix and MyiQ2, Biorad). Primers were used at 200 nM. 59 UTR analysis. 59 UTRs of the 144 downregulated mTOR target genes were obtained using the known gene ID from the UCSC Genome Browser (GRCh37/ hg19). Target versus non-target mRNAs were compared for 59 UTR length, %G1C content and Gibbs free energy by the Wilcoxon two-sided test. Multiple E m (expectation maximization) for Motif Elicitation (MEME) and Find Individual Motif Occurrences (FIMO) was used to derive the PRTE and determine its enrichment in the 144 mTOR-sensitive genes compared a background list of 3,000 genes. The Database of Transcriptional Start Sites (DBTSS Release 8.0) was used to identify putative 59 TOP genes and putative transcription start sites in the 144 mTOR target genes. Luciferase assay. PC3 4EBP1 M cells were treated with 1 mg ml 21 doxycycline (Sigma) for 24 h. Cells were transfected with various pGL3-Promoter constructs using lipofectamine 2000 (Invitrogen). After 24 h, cells were collected. 20% of the cells were aliquoted for RNA isolation. The remaining cells were used for the luciferase assay per the manufacturer's protocol (Promega). Samples were measured for luciferase activity on a Glomax 96-well plate luminometer (Promega). Firefly luciferase activity was normalized to luciferase mRNA expression levels. Kinase assays. mTOR activity was assayed using LanthaScreen Kinase kit reagents (Invitrogen) according to the manufacturer's protocol. PI(3)K a, b, c and d activity were assayed using the PI(3)K HTRF assay kit (Millipore) according to the manufacturer's protocol. The concentration of INK128 necessary to achieve inhibition of enzyme activity by 50% (IC 50 ) was calculated using concentrations ranging from 20 mM to 0.1 nM (12-point curve). IC 50 values were determined using a nonlinear regression model (GraphPad Prism 5). Cell proliferation assay. PC3 cells were treated with the appropriate drug for 48 h, and proliferation was measured using CellTiter-Glo Luminescent reagent (Promega) per the manufacturer's protocol. The concentration of INK128 necessary to achieve inhibition of cell growth by 50% (IC 50 ) was calculated using concentrations ranging from 20.0 mM to 0.1 nM (12-point curve). Mouse xenograft study. Nude mice were inoculated subcutaneously in the right subscapular region with 5 3 10 6 MDA-MB-361 cells. After tumours reached a size of 150-200 mm 3 , mice were randomly assigned into vehicle control or treatment groups. INK128 was formulated in 5% polyvinylpropyline, 15% NMP, 80% water and administered by oral gavage at 0.3 mg kg 21 and 1 mg kg 21 daily. Pharmacokinetic analysis. The area under the plasma drug concentration versus time curves, AUC 0{tlast ð Þ and AUC (02inf) , were calculated from concentration data using the linear trapezoidal rule. The terminal t 1/2 in plasma was calculated from the elimination rate constant (lz), estimated as the slope of the log-linear terminal portion of the plasma concentration versus time curve, by linear regression analysis. The bioavailability (F) was calculated using F 5 (AUC (02last),po D i.v. )/ (AUC (02last),iv D p.o. )3100%, where D i.v. and D p.o. are intravenous and oral doses, respectively. C max was a highest drug concentration in plasma after oral administration. T max was the time at which C max is observed after extravascular administration of drug. T last was the last time point a quantifiable drug concentration can be measured. Metabolic stability assay. In vitro metabolic stability of INK128 was evaluated after incubation with liver microsomes or liver S9 fractions from various species in the presence of NADPH. The half-life of INK128 was estimated by log linear regression analysis. CYP assay. INK128 inhibition of CYP450 isoforms in human liver microsomes was determined with isoform-specific substrates at concentrations approximately equal to the concentration at which the rate of the reaction is half-maximal (K m ) for the individual isoforms: CYP1A2, CYP2C8, CYP2C9, CYP2C19, CYP2D6 and CYP3A4. Pharmaceutical property assays. The percentage of protein binding of INK128 was determined in mouse, rat, dog, monkey and human plasma at CEREP. The IC 50 for the inhibitory effect of INK128 on hERG potassium channel was determined at RESEARCH ARTICLE
